ArticleMicrobiology spectrum2026
Development and characterization of mouse-adapted recombinant SARS-CoV-2 expressing reporter genes.
Sara H Mahmoud, Nathaniel Jackson, Ramya S Barre, Yao Ma, Mahmoud Bayoumi, Esteban M Castro, Shahrzad Ezzatpour, Richard K Plemper, Stanley Perlman, Chengjin Ye and 1 more
Abstract read
In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Sara H MahmoudHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Nathaniel JacksonHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Ramya S BarreHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Yao MaHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Mahmoud BayoumiHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Esteban M CastroHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0002-2540-8382 Shahrzad EzzatpourHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Richard K PlemperCenter for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Chengjin YeHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0002-1934-9494 Luis Martinez-SobridoHost-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0001-7084-0804 Funding
Project 6 - Development of Antivirals against AlphavirusesU19AI171403 · NIAID · EMORY UNIVERSITY · PI George Robert Painter, Richard K. Plemper · 2022 to 2026
$59.7MRole of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7MMechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2MScience as a Team Sport: Leveling the playing field and setting the rules of engagement.T32GM148752 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GRIFFITH, ANN VENABLES, OYAJOBI, BABATUNDE OLUKAYODE · 2023 to 2024
$874kNIAID NIH HHS R01 AI129269NIAID NIH HHS R01 AI161363NIAID NIH HHS U19 AI171403NIGMS NIH HHS T32 GM148752
6 · The paper itselfAbstract
SARS-CoV-2 is the causative agent of COVID-19. The ancestral SARS-CoV-2 Washington-1 (WA1) strain does not infect standard laboratory mouse strains, necessitating the use of mouse-adapted (MA) viruses. A MA SARS-CoV-2, SARS-CoV-2-N501Y MA30 (hereafter MA30), has been developed to allow infection of wild-type (WT) mice. However, SARS-CoV-2 MA30 cannot be tracked IMPORTANCE: Mouse-adapted (MA) SARS-CoV-2 that infect wild-type (WT) mice are critical tools for preclinical studies. While the previously described SARS-CoV-2-N501Y MA30 enables infection of WT mice, it does not allow non-invasive tracking of viral infections. Recombinant viruses expressing reporter genes enable real-time monitoring of infection dynamics, opening an avenue to study viral tropism and easily evaluate prophylactic and therapeutic approaches. They furthermore support longitudinal studies, which reduces the number of research animals required. Here, we show that a recombinant (r)SARS-CoV-2 expressing fluorescent (mCherry) and nanoluciferase (Nluc) reporter genes, alone or in combination, can be used to track viral infections
Indexed as
COVID-19Genes, ReporterSARS-CoV-2AnimalsChlorocebus aethiopsDisease Models, AnimalFemaleHumansLuciferasesMiceMice, Inbred BALB CMice, Inbred C57BLVero CellsVirus ReplicationLuciferasesbioluminescence imagingmouse-adapted virusreporter genesSARS-CoV-2viral pathogenesis
Identifiers
PMID42446208
PMCPMC13436019
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390